HC Wainwright Issues Pessimistic Forecast for Savara (NASDAQ:SVRA) Stock Price

Savara (NASDAQ:SVRA) had its target price decreased by HC Wainwright from $10.00 to $6.00 in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.46) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

Several other equities research analysts have also recently commented on the company. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday. JMP Securities restated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Savara Trading Down 6.6 %

SVRA opened at $2.98 on Wednesday. Savara has a twelve month low of $2.83 and a twelve month high of $5.70. The company has a fifty day moving average of $3.88 and a 200-day moving average of $4.19. The stock has a market cap of $511.43 million, a PE ratio of -6.93 and a beta of 1.02. The company has a quick ratio of 11.31, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, sell-side analysts predict that Savara will post -0.44 EPS for the current year.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co bought a new position in Savara in the first quarter worth approximately $35,000. Choreo LLC acquired a new position in shares of Savara during the second quarter worth approximately $59,000. DRW Securities LLC bought a new position in shares of Savara in the 2nd quarter worth $62,000. Principal Financial Group Inc. lifted its holdings in shares of Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Savara by 258.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after purchasing an additional 18,534 shares during the period. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.